Phase II Study of Docetaxel+Bevacizumab with non-squamous non-small cell lung cancer for patients pretreated with chemotherapy
- Conditions
- on-small-cell lung cancer
- Registration Number
- JPRN-UMIN000005077
- Lead Sponsor
- Tochigi Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 22
Not provided
1)Symptomatic Brain metastasis or expected bleeding. 2) history of active double cancer within 5 years. 3) Severe infection 4) History of hemoptysis with 2.5mL or more. 5) Continued bloody phlegm. 6) Receiving anticoagulant drug(including Aspirin over 325mg/day). 7) Perforation of the digestive tract or history of the perforation of the digestive tract within the past one year. 8) Severe comorbidity (heart failure Tendency to hemorrhages uncontrollable hypertension, uncontrollable diabetes, etc) 9) Arterial thromboembolism and Venous thromboembolism within the past one year. 10)Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 11) Neuropathy or edema 12) History of hypersensitivity reaction to drugs formulated with polysorbate. 13) Planning of surgery or thoracic radiotherapy during the trial. 14) Major surgical procedure 15) With a history of drug sensitivity. 16) Pregnant or lactating women or those who declined contraception. 17) Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Response rate Overall survival Safety PFS,RR,OS,DCR(harboring EGFR mutation or not)